Currently out of the existing stock ratings of Bryan Brokmeier, 33 are a BUY (97.06%), 1 are a HOLD (2.94%).

Bryan Brokmeier

Work Performance Price Targets & Ratings Chart

Analyst Bryan Brokmeier, carries an average stock price target met ratio of 80% that have a potential upside of 61.54% achieved within 472 days. Previously, Bryan Brokmeier worked at CANTOR FITZGERALD.

Bryan Brokmeier’s has documented 61 price targets and ratings displayed on 12 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on TTOO, T2 Biosystms at 03-May-2017.

Wall Street Analyst Bryan Brokmeier

Analyst best performing recommendations are on NEON.
The best stock recommendation documented was for NEON at 4/26/2017. The price target of $11 was fulfilled within 16 days with a profit of $6.2 (36.05%) receiving and performance score of 22.53.

Average potential price target upside

of $26.9 (19.84%) on WAT (WATERS).
of $11 (25.91%) on PKI (PERKINELMER).
of $7.55 (40.39%) on NEON.

PACB Pacific Biosciences of California VCYT Veracyte WAT Waters CERS Cerus FLDM Fluidigm NEO NeoGenomics PKI PerkinElmer TTOO T2 Biosystms ANGO AngioDynamics LAB Standard Biotools NEON TMO Thermo Fisher Scientific

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Luke Sergott (BARCLAYS)